logo
Volume 13, Issue 2 (4-2026)                   jbrms 2026, 13(2): 40-47 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soltani B, Ahifar A, Ghaderi R, Moradians V. Frequency of Peripheral Blood Eosinophilia in Chronic Pulmonary Diseases with Obstructive Pattern in Spirometry. jbrms 2026; 13 (2) :40-47
URL: http://jbrms.medilam.ac.ir/article-1-1034-en.html
Frequency of Peripheral Blood Eosinophilia in Chronic Pulmonary Diseases with Obstructive Pattern in Spirometry
Bahareh Soltani , Ayat Ahifar , Reza Ghaderi , Vahan Moradians
Department of internal medicine, Hazrat Rasoul Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , Dr.ahifar@gmail.com
Abstract:   (336 Views)

Introduction: Eosinophils are inflammatory cells that perform diverse functions and play roles in both homeostasis and disease in various tissues. Evidence indicates that many patients with chronic respiratory conditions, including asthma and COPD, exhibit persistent eosinophilic airway inflammation. This study aimed to evaluate the prevalence of blood eosinophilia in patients with obstructive patterns on spirometry.
Materials & Methods: This cross-sectional study was conducted on patients attending the Hazrat Rasoul Akram Hospital, affiliated with Iran University of Medical Sciences. Patients who underwent spirometry and had peripheral blood tests were included in the study. Information regarding age, gender, body mass index, underlying diseases, smoking habits, medication use, spirometry results, and complete blood count (CBC) was collected and analyzed statistically.
Results:  A total of 103 participants were selected based on the inclusion criteria and participated in the study. In the current study, 8 patients (7.8%) were eosinophilic-positive and 95 patients (92.2%) were eosinophilic-negative. The mean FEV1 in the eosinophilic-negative group was 63.25% (with a standard deviation of 20.585), while in the eosinophilic-positive group it was 60.00% (with a standard deviation of 14.203). Statistical tests confirmed no significant difference between the two groups, suggesting that reduced FEV1 was not associated with blood eosinophilia in this population. Additionally, the mean FEV1/FVC ratio in the eosinophilic-negative group was 80.72% (with a standard deviation of 17.10), and in the eosinophilic-positive group it was 77.33% (with a standard deviation of 15.62), which also showed no statistically significant difference.
Conclusion:  This study found no significant association between blood eosinophilia and demographic or pulmonary function variables in patients with obstructive patterns on spirometry. Future studies with more precise designs and larger sample sizes may clarify the role of eosinophilia in prognosis and treatment response.
 

Keywords: Pulmonary Disease, Chronic Obstructive, Eosinophilia
Full-Text [PDF 589 kb]   (94 Downloads)    
Type of Study: Research | Subject: Hematology
Received: 2025/10/1 | Accepted: 2025/10/14 | Published: 2026/04/6
References
1. Wang X, Mensinga TT, Schouten JP, Rijcken B, Weiss ST. Determinants of maximally attained level of pulmonary function. Am J Respir Crit Care Med. 2004;169(8):941-9. [DOI:10.1164/rccm.2201011]
2. Lin CH, Cheng SL, Chen CZ, Chen CH, Lin SH, Wang HC. Current Progress of COPD Early Detection: Key Points and Novel Strategies. Int J Chron Obstruct Pulmon Dis. 2023;18:1511-24. [DOI:10.2147/COPD.S413969]
3. Bui DS, Lodge CJ, Burgess JA, Lowe AJ, Perret J, Bui MQ, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med. 2018;6(7):535-44. [DOI:10.1016/S2213-2600(18)30100-0]
4. Mogensen I, Vonk JM, Wijnant SRA, Zhou X, Boezen HM, Brusselle G, et al. Blood eosinophil level and lung function trajectories: cross-sectional and longitudinal studies in European cohorts. ERJ Open Res. 2020;6(4). [DOI:10.1183/23120541.00320-2020]
5. DiLillo KM, Norman KC, Freeman CM, Christenson SA, Alexis NE, Anderson WH, et al. A blood and bronchoalveolar lavage protein signature of rapid FEV(1) decline in smoking-associated COPD. Sci Rep. 2023;13(1):8228. [DOI:10.1038/s41598-023-32216-0]
6. Pignatti P, Visca D, Cherubino F, Zampogna E, Lucini E, Saderi L, et al. Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients. Respir Res. 2019;20(1):145. [DOI:10.1186/s12931-019-1111-1]
7. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377(17):1613-29. [DOI:10.1056/NEJMoa1708208]
8. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335-49. [DOI:10.2147/COPD.S152291]
9. Yii ACA, Tay TR, Choo XN, Koh MSY, Tee AKH, Wang DY. Precision medicine in united airways disease: A "treatable traits" approach. Allergy. 2018;73(10):1964-78. [DOI:10.1111/all.13496]
10. Cui Y, Chen Y. Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker. J Transl Int Med. 2023;11(3):193-7. [DOI:10.2478/jtim-2023-0096]
11. Yang J, Yang J. Association Between Blood Eosinophils and Mortality in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. Int J Chron Obstruct Pulmon Dis. 2021;16:281-8. [DOI:10.2147/COPD.S289920]
12. Cui Y, Zhang W, Ma Y, Zhan Z, Chen Y. Stability of blood eosinophils in acute exacerbation of chronic obstructive pulmonary disease and its relationship to clinical outcomes: a prospective cohort study. Respir Res. 2021;22(1):301. [DOI:10.1186/s12931-021-01888-5]
13. Mogensen I, Alving K, Jacinto T, Fonseca J, Janson C, Malinovschi A. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12. Clin Exp Allergy. 2018;48(8):935-43. [DOI:10.1111/cea.13137]
14. Frette C, Annesi I, Korobaeff M, Neukirch F, Dore MF, Kauffmann F. Blood eosinophilia and FEV1. Cross-sectional and longitudinal analyses. Am Rev Respir Dis. 1991;143(5 Pt 1):987-92. [DOI:10.1164/ajrccm/143.5_Pt_1.987]
15. Hancox RJ, Pavord ID, Sears MR. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur Respir J. 2018;51(4). [DOI:10.1183/13993003.02536-2017]
16. Müllerová H, Hahn B, Simard EP, Mu G, Hatipoğlu U. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts. Int J Chron Obstruct Pulmon Dis. 2019;14:683-92. [DOI:10.2147/COPD.S194367]
17. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-47.e10. [DOI:10.1016/j.jaci.2018.04.010]
18. Zeiger RS, Tran TN, Butler RK, Schatz M, Li Q, Khatry DB, et al. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease. J Allergy Clin Immunol Pract. 2018;6(3):944-54.e5. [DOI:10.1016/j.jaip.2017.10.004]
19. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956-67. 10.1016/S2213-2600(17)30432-0
20. Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal. 2017;50(5):1701162. [DOI:10.1183/13993003.01162-2017]
21. Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020;21(1):240. [DOI:10.1186/s12931-020-01482-1]
22. Han Y, Hua J, He B, Zhang J. Inhaled Antibiotics and Airway Bacterial Decolonization for Patients with Chronic Obstructive Pulmonary Disease: The Rationale and Future. J Transl Int Med. 2022;10(3):181-4. [DOI:10.2478/jtim-2022-0005]
23. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. [DOI:10.1186/1465-9921-11-122]
24. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5(9):747-59. [DOI:10.1016/S2213-2600(17)30217-5]
25. Tamondong-Lachica DR, Skolnik N, Hurst JR, Marchetti N, Rabe APJ, Montes de Oca M, Celli BR. GOLD 2023 Update: Implications for Clinical Practice. Int J Chron Obstruct Pulmon Dis. 2023;18:745-54. [DOI:10.2147/COPD.S404690]
26. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977-9. [DOI:10.1038/nm.3300]
27. Dixon AE, Johnson SE, Griffes LV, Raymond DM, Ramdeo R, Soloveichik A, et al. Relationship of adipokines with immune response and lung function in obese asthmatic and non-asthmatic women. J Asthma. 2011;48(8):811-7. [DOI:10.3109/02770903.2011.613507]
28. Janson C, Bjermer L, Lehtimäki L, Kankaanranta H, Karjalainen J, Altraja A, et al. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges. Eur Clin Respir J. 2022;9(1):2040707. [DOI:10.1080/20018525.2022.2040707]
29. Navabi B, Upton JE. Primary immunodeficiencies associated with eosinophilia. Allergy Asthma Clin Immunol. 2016;12:27. [DOI:10.1186/s13223-016-0130-4]
30. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435-42. [DOI:10.1016/S2213-2600(15)00.]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.